COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08 (2-92) Sheet 1 of 2

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(Use several sheets if necessary)

OPE (Use several sheets if necessary)

Mailing Date August 32, 2002

SEP 0 9 TRACE ANTIBODY

RECEIVED

SEP 1 1 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
40	1.	02/1993	5,189,042	Goulet et al.	514	291	,
4	2.	09/1997	5,672,491	Khosla et al.	435	148	
. 6	3.	01/1998	5,712,146	Khosla et al.	,435	252.35	
8	4.	10/1999	5,968,921	Gold	514	183	
4	5.	11/2000	6,150,513	Wu	536	23.2	
8	6.	04/2001	6,210,974	Gold	436	501	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transl YES	lation NO
6	7.	07/05/1989	EP 0323042A	EPO	-			
ζ,	8.	02/28/1990	EP 0356399A	EPO		Ť		
J,	9.	01/02/1992	EP 0463690A	EPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
4	10.	Chen T.S. et al. (1992). "Microbial Transformation of Immunosupressive Compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 9500520 by Actinomycete sp. ATCC 53828," <i>J Antibiot</i> 45(4):577-580.
4	11.	Dumont F.J. et al. (1992). "The Immunosupressive and Toxic Effects of FK-506 Are Mechanically Related: Pharmacology of a Novel Antagonist of FK-506 and Rapamycin," <i>J of Exp Medicine</i> 176(3):751-760.
4	12.	Gold et al., (1995) Journal of Neuroscience 15:7509-7516
4	13.	Gold et al., (1999) J. Pharm. Exp. Ther. 289(3):1202-1210
8	14.	Harrison's Principles of Internal Medicine, 14th Edition, 1998, McGraw Hill, Chapters 14,20,21,64-67
4	15.	Iwasaki et al., (1993) Drug Metabolism and Disposition 21:971-977
ζ,	16.	Iwasaki et al., (1995) Drug Metabolism and Disposition 23:28-34

EXAMINER:

4 Peller

DATE CONSIDERED:

sd-103837

2/3/09

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08 (2-92) Sheet 2 of 2

Form PTO-1449			Docket Number 300622002611	Application Number 09/940,316				
TRUBON	RMA1	TION DISCLOSURE CITATION	Applicant					
IN AN APPLICATION			Christopher REEVES et al.					
p 0 9 2000	₹) ((Use several sheets if necessary)	Filing Date August 27, 2001	Group Art Unit 1652				
			Mailing Date August 36, 2002					
RACCIARY								
· Car	17.	Kawai et al., (1993) FEBS Letters 31	6(2):107-113					
4	18.	Khosla C. (1997). "Harnessing the Bi Chemical Reviews 97(7):2577-2590.	Khosla C. (1997). "Harnessing the Biosynthetic Potential of Modular Polyketide Synthases,"					
8	19.	Lyons et al., (1994) Proc. Natl. Acad.	. Sci. USA 91:3191-3195 RECEIVET					
4	20.	Motamedi et al., (1996) J. Bacteriol.	178:5243-5248	CCO 1 1 0000				
G	21.	Motamedi et al., (1997) Eur. J. Bioch	em. 244:78-80	SEP 1 1 2002				
4	22.	Motamedi and Shafiee, (1998) Eur. J.	Biochem. 256:528	TECH CENTER 1600/2				
4	23.	Reynolds K.A. et al. (1997). "Rapamy Pharm Sci 82:497-520.	Reynolds K.A. et al. (1997). "Rapamycin, FK506, and Ascomycin-related Compounds," Drugs					
,	24.	Shafiee A. et al. (1993). "Enzymatic s Desmethylated Immunomycins (Asco	Shafiee A. et al. (1993). "Enzymatic synthesis and Immunosupressive Activity of Novel Desmethylated Immunomycins (Ascomycins)," J Antibiot 46(9):1397-1405.					
Sp	25.	Shiraga et al., (1994) Biochem. Pharm	Shiraga et al., (1994) Biochem. Pharmacol. 47:727-735					
(h)	26.	Stassi D.L. et al. (1998). "Ethyl-substituted Erythromycin Derivatives Produced by Directed Metabolic Engineering," <i>Proc Natl Acad Sci USA</i> 95 (13):7305-7309.						
4	27.	Steiner et al., (1997) Proc. Natl. Acad. Sci. USA 94:2019-2024						
4	28.	Vincent et al., (1992) Arch. Biochem.	Biophys. 294:454-460					
4	29.	Wu et al., (2000) Gene 251:81-90						
			. ·					
			,					
			•					
EXAMIN	ER:	2 12 12	DATE CONSIDERED:	1/3/02				